WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, today announced that John A. Kollins has joined the Company as Senior Vice President and Chief Business Officer. Mr. Kollins brings with him a proven track record of completing major in-licensing and out-licensing transactions. As Chief Business Officer for OXiGENE, Mr. Kollins will be responsible for all business development activities as well as commercial strategy for OXiGENE.
